Advertisement
Neratinib and trastuzumab emtansine (T-DM1) combination potent and well tolerated
Maciejewski honored for work in bone marrow failure syndromes
Results suggest: Offer broad testing to all of them
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Clinical efficacy uncompromised in previously untreated patients
Clinical trials testing olaparib in breast cancer
Learn about featured cancer clinical trials currently enrolling, or search our cancer clinical trials database for all open and accruing studies
Finding has potential to improve treatment
Drug targets CD33 to produce high remission rates
Trial results reported for first molecularly targeted therapy
Advertisement
Advertisement